Pierre Fenaux
Assistance Publique - Hopitaux de Paris (AP-HP) · Hôpital Saint Louis · ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FRANCE
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
22
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in acute myeloid leukemia
108
PubMed author-name match
Trials
Studies that name Pierre Fenaux as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:41 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06250595 · European Rare Blood Disorders Platform (ENROL)Hospital Universitari Vall d'Hebron Research Institute · recruiting · Anemia, Bone Marrow Failure, Bleeding Disorder · principal investigator
- Ph2NCT05935202 · Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte MembranopathiesEuroBloodNet Association · not yet recruiting · Hereditary Red Blood Cell Disorder (Disorder) · study chair
- Ph2NCT05768711 · Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)Groupe Francophone des Myelodysplasies · active not recruiting · Chronic Myeloid Leukemia · principal investigator
- N/ANCT04889729 · GENOMED4ALL: Improving MDS Classification and Prognosis by AIIstituto Clinico Humanitas · unknown · Myelodysplastic Syndromes · principal investigator
- Ph2NCT04857645 · ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML PatientsGroupe Francophone des Myelodysplasies · completed · MDS, AML · principal investigator
- Ph2NCT04827719 · BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDSGroupe Francophone des Myelodysplasies · completed · Myelodysplastic Syndromes, Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT03588078 · Study of the Safety and Efficacy of APR-246 in Combination With AzacitidineGroupe Francophone des Myelodysplasies · completed · Myelodysplastic Syndrome With Gene Mutation, Acute Myeloid Leukemia With Gene Mutations, Myeloproliferative Neoplasm · principal investigator
- Ph2NCT02985190 · A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory DisordersGroupe Francophone des Myelodysplasies · completed · MDS, Systemic Autoimmune Diseases · study director
- N/ANCT02938858 · French Registry of First-line Treatment of Acute Promyelocytic LeukemiaGroupe Francophone des Myelodysplasies · completed · Acute Promyelocytic Leukemia · principal investigator
- Ph1NCT02323139 · A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome PatientsGroupe Francophone des Myelodysplasies · completed · MDS · study director
- Ph1/Ph2NCT02323178 · A Study of Eltrombopag in Patients With CMML and ThrombocytopeniaGroupe Francophone des Myelodysplasies · completed · CMML, Thrombocytopenia · study director
- Ph2NCT02197676 · A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a ResponseGroupe Francophone des Myelodysplasies · completed · MDS · principal investigator
- Ph1/Ph2NCT01813838 · GFM-Acadesine: A Phase I-II Trial of AcadesineGroupe Francophone des Myelodysplasies · terminated · SMD · principal investigator
- Ph2NCT01748240 · Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine FailureGroupe Francophone des Myelodysplasies · terminated · Myelodysplastic Syndrome · study director
- Ph1/Ph2NCT01718366 · A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDSGroupe Francophone des Myelodysplasies · unknown · MDS · study director
- Ph2NCT01342692 · Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic SyndromesAssistance Publique - Hôpitaux de Paris · unknown · MDS · principal investigator
- Ph1/Ph2NCT01324960 · Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic SyndromesGroupe Francophone des Myelodysplasies · withdrawn · Myelodysplastic Syndromes · principal investigator
- Ph1NCT01152346 · Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) PatientsBioniche Pharma USA LLC · completed · Myelodysplastic Syndrome · study chair
- Ph3NCT00599937 · APL93: Timing of CxT and Role of MaintenanceGroupe d'etude et de travail sur les leucemies aigues promyelocytaires · completed · Leukemia, Promyelocytic, Acute · principal investigator
- Ph3NCT00591526 · A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)Groupe d'etude et de travail sur les leucemies aigues promyelocytaires · completed · Leukemia, Promyelocytic, Acute · principal investigator
- Ph2NCT00424229 · Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]Groupe Francophone des Myelodysplasies · unknown · Myelodysplastic Syndromes · study director
- Ph2NCT00241241 · Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia VeraPV-Nord · completed · Polycythemia Vera · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:41 UTC. The ranking covers the 200 most relevant of 108 PubMed records, and a shared surname and initials can bring in a namesake. All 108 on PubMed
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.N Engl J Med · 20202,533 citationsRCR 110.4
- All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.Blood · 19901,323 citationsRCR 31.2
- 839 citationsRCR 20.7
- Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.J Clin Oncol · 2010804 citationsRCR 17.3
- 575 citationsRCR 12.5
- 455 citationsRCR 11.4
- 437 citationsRCR 23.2
- 402 citationsRCR 9.9
- All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.Blood · 1995371 citationsRCR 8.0
- 284 citationsRCR 7.5